In a report released today, Matthew Mishan from KeyBanc maintained a Buy rating on Avanos Medical Inc (AVNS), with a price target of $65. The company’s shares opened today at $50.15.
According to TipRanks.com, Mishan is a 5-star analyst with an average return of 18.7% and a 80.4% success rate. Mishan covers the Healthcare sector, focusing on stocks such as Cantel Medical Corp, Cooper Co, and Hill-Rom.
Avanos Medical Inc has an analyst consensus of Moderate Buy, with a price target consensus of $53.33.
See today’s analyst top recommended stocks >>
Based on Avanos Medical Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $2.2 million. In comparison, last year the company had a net profit of $32.8 million.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AVNS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avanos Medical, Inc. is a medical technology company focused on preventing infection, eliminating pain and speeding recovery for healthcare providers and their patients. It operates through the following business segments: Surgical & Infection Prevention and Medical Devices.
